2022.01.11 Press release

--To the press -

FRONTEO Achieves Target Number of Registered Cases in "Conversational Dementia Diagnosis Support AI Program" Clinical Trials

FRONTEO Inc.
Masahiro Morimoto, President and CEO
2-12-23 Konan, Minato-ku, Tokyo
(Code number: 2158 TSE Mothers)

 FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereafter FRONTEO) achieved the target number of cases in the clinical trial of the "Conversational Dementia Diagnosis Support AI Program" in December 2021. We will inform you that the case registration has been completed.

 

 This clinical trial was started in April 2021 after administrative consultation with the Pharmaceuticals and Medical Devices Agency (PMDA).Due to the fact that it is Japan's first language-based AI program medical device, various adjustments were required in conducting clinical trials, but related organizations and the conducting medical institutions and subjects who participated in the clinical trials With the cooperation, we were able to smoothly achieve case registration.In the future, we will analyze the accumulated clinical data and proceed with processes such as application for regulatory approval.This AI program aims to be launched in 4.

 

 By approving this AI program and utilizing it in the medical field, FRONTEO will detect dementia at an early stage and prevent its aggravation, reduce the medical disparity between regions in dementia medical care, reduce the burden on medical staff and patients, and patients.・ We believe that we can contribute to improving the QOL of our families and greatly contribute to measures against dementia in Japan.We will endeavor to make this AI program available in clinical practice as soon as possible.

 


■ About conversational dementia diagnosis support AI program
 URL:https://lifescience.fronteo.com/aidevice/dementia/
The "Conversational Dementia Diagnosis Support Program" (AI medical device) uses FRONTEO's original natural language analysis AI "Concept Encoder" to enable cognitive dysfunction from daily conversation between a doctor and a patient for about 5 to 10 minutes. It is a system that can screen. FRONTEO believes that this system can contribute to the progress of digital medical care such as telemedicine and the efficiency and standardization of medical care, in addition to measures against dementia, which is an important issue in Japan, which has entered a super-aging society. I am. We started clinical trials in April 2021 and are currently working toward early manufacturing and marketing approval and early launch.Patent registration number: Patent No. 4

■ About Concept Encoder URL:https://lifescience.fronteo.com/technology/conceptencoder/
"Concept Encoder" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. Concept Encoder can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals, and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

■ About FRONTEO URL:https://www.fronteo.com/
FRONTEO uses the in-house developed AI engines "KIBIT", "Concept Encoder", and "Looca Cross" that specialize in natural language processing to extract meaningful and important information from a huge amount of text data, and is used by companies. A data analysis company that supports business. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support corporate international litigation. Has been deployed.Based on the AI ​​technology cultivated in this business, we will expand the business field to the life science field, business intelligence field, and economic security from 8, and by using AI to "turn text data into knowledge", We contribute to solving various corporate issues such as drug discovery support, dementia diagnosis support, financial, personnel, and sales support. Listed on TSE Mothers on June 2014, 2007. Obtained a first-class medical device manufacturing and sales business license in January 6 (permit number: 26B2021X1), and notified the managed medical device sales business in September of the same year (notification number: 13 Minato Misei Equipment No. 1).The capital is 10350 thousand yen (as of March 9, 3).

* FRONTEO, KIBIT, conceptencoder, and Amanogawa are registered trademarks of FRONTEO in Japan.

<Contact information for the press>

Public Relations Officer, FRONTEO Inc.

Email: pr_contact@fronteo.com

 

<Inquiries about Life Science AI Business>

FRONTEO Inc. Life Science AI Business Headquarters

https://lifescience.fronteo.com/contact

ja 日本語
Machine Translation by Google. : close x